TherapeuticsMD, Inc. (TXMD) News

TherapeuticsMD, Inc. (TXMD): $2.14

0.07 (+3.38%)

POWR Rating

Component Grades













Filter TXMD News Items

TXMD News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

TXMD News Highlights

  • For TXMD, its 30 day story count is now at 2.
  • Over the past 19 days, the trend for TXMD's stories per day has been choppy and unclear. It has oscillated between 1 and 1.

Latest TXMD News From Around the Web

Below are the latest news stories about TherapeuticsMD Inc that investors may wish to consider to help them evaluate TXMD as an investment opportunity.

TherapeuticsMD, Inc. (NASDAQ:TXMD): Is Breakeven Near?

We feel now is a pretty good time to analyse TherapeuticsMD, Inc.'s ( NASDAQ:TXMD ) business as it appears the company...

Yahoo | January 25, 2022

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

Good morning, trader!

William White on InvestorPlace | January 6, 2022

FDA Approves TherapeuticsMD's Low Dose Bijuva

TherapeuticsMD Inc (NASDAQ: TXMD) is trading sharply higher after it announced that the FDA approved a low dose version of Bijuva, an oral hormone therapy to treat women with vasomotor symptoms due to menopause. In a regulatory filing, TherapeuticsMD said that on December 28, the agency cleared its supplemental marketing application for Bijuva, seeking approval for the capsule at the 0.5 mg/100 mg dose level. Related Link: TherapeuticsMD, Amneal Settle US Patent Litigation For Bijuva. The plans

Yahoo | January 4, 2022

Implied Volatility Surging for TherapeuticsMD (TXMD) Stock Options

Investors need to pay close attention to TherapeuticsMD (TXMD) stock based on the movements in the options market lately.

Yahoo | December 28, 2021

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

Welcome back, investor!

William White on InvestorPlace | December 13, 2021

TherapeuticsMD's Birth Control Med Receives FDA Response Letter To Revise Manufacturing Testing Limits

TherapeuticsMD Inc (NASDAQ: TXMD) said that the FDA could not approve revisions to certain manufacturing testing limits for Annovera through the supplemental marketing application previously submitted by the Company. The supplemental application requested minor revisions to the in vitro release testing specification for Annovera to allow for normal commercial manufacturing variation. Also, see Benzinga's Full FDA Calendar here. The Company submitted the proposed revisions to the manufacturing te

Yahoo | December 13, 2021

U.S. Food and Drug Administration (FDA) Responds to Request From TherapeuticsMD to Revise Certain Manufacturing Testing Limits for ANNOVERA®

BOCA RATON, Fla., December 10, 2021--TherapeuticsMD, Inc. (NASDAQ:TXMD) ("TXMD" or the "Company"), an innovative, leading women’s healthcare company, today announced that the FDA determined that it could not approve revisions to certain manufacturing testing limits for ANNOVERA through the sNDA previously submitted by the Company. In its complete response letter, the FDA provided recommendations and requested additional information that could support approval of revisions to certain manufacturin

Yahoo | December 10, 2021

TherapeuticsMD Settles U.S. Patent Litigation with Amneal for BIJUVA® (Estradiol and Progesterone) — Allowing for a May 25, 2032 Generic Entry Date

BOCA RATON, Fla., December 08, 2021--TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative, leading women’s healthcare company, today announced the settlement of the previously disclosed U.S. patent litigation for BIJUVA® with Amneal Pharmaceuticals, Inc., Amneal Pharmaceuticals, LLC, and Amneal Pharmaceuticals of New York LLC (collectively "Amneal").

Yahoo | December 8, 2021

TherapeuticsMD (NASDAQ:TXMD) investors are sitting on a loss of 90% if they invested five years ago

Long term investing works well, but it doesn't always work for each individual stock. We really hate to see fellow...

Yahoo | November 24, 2021

Therapeuticsmd Insider Trades $580K In Company Stock

Cooper C Collins, Insider at Therapeuticsmd (NASDAQ:TXMD), made a large insider buy on November 18, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission on Thursday showed that Collins purchased 1,000,000 shares of Therapeuticsmd at $0. Following the transaction, Collins now owns 2,236,864 shares of Therapeuticsmd, worth $1,324,223.00. Therapeuticsmd shares are trading up 4.19% at $0.59 at the time of this writing on Monday morning. Now t

Yahoo | November 22, 2021

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.5564 seconds.